Page last updated: 2024-10-21

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Anti-MuSK Myasthenia Gravis

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Anti-MuSK Myasthenia Gravis in 1 studies

alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Schäfer, J1
Christensen, PB1
Jensen, K1

Other Studies

1 other study available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Anti-MuSK Myasthenia Gravis

ArticleYear
AMPA and NMDA receptor antibody autoimmune encephalitis preceded by ocular myasthenia gravis: a case report.
    BMC neurology, 2023, Mar-10, Volume: 23, Issue:1

    Topics: Adult; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anti-N-Methyl-D-Aspartate Receptor

2023